Liver Cancer

  • CALGB 80802- A Phase III Randomized Study of Sorafenib (IND 69896, NSC 724772) plus Doxorubicin versus Sorafenib in Patients with Locally Advanced or Metastatic Liver Cancer (Temporarily Suspended effective 11/8/2013)